ArticleCancer cell2025
Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity.
Abstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Route of BCG administration determines success.Human vaccines & immunotherapeutics · 2026Review
- Mechanisms of systemic immune modulation in tumor development: Interactions across lymph nodes, bone marrow, and blood.Cancer metastasis reviews · 2026Review
- Neutrophils in cancer.Nature reviews. Cancer · 2026Review
- Maladaptive trained immunity as a hematopoietic stem cell driver of inflammaging.Nature aging · 2026Article
- Long-Term Impact of Historical BCG Vaccination Policies on Parkinson's Disease Risk: A Hypothesis-Generating Retrospective Cohort Analysis.Biomedicines · 2026Article
- Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models.Science translational medicine · 2026Article
- Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer.The Journal of clinical investigation · 2026Article
- Trained immunity modulators: A new frontier in immunoregulation and disease intervention.Journal of advanced research · 2026Review
- Enhanced Anti-Lung Cancer Efficacy of Neo-BCV Combined with Cisplatin: Immune Activation and Tumor Microenvironment Remodeling.Vaccines · 2026Article
- Albumin-Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- BCG-trained macrophages promote pan-anti-tumor activity through epigenetic rewiring of NOX2-ROS axis.Journal of experimental & clinical cancer research : CR · 2026Article
- How to Employ Trained Immunity and Trained Immunity-Based Vaccines to Inhibit Allergic Inflammation.Vaccines · 2026Review
- The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.The Journal of clinical investigation · 2026Review
- Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer.Immune network · 2026Review
- The TRIM-cancer paradox: BCG as a programmable vaccine platform and a mechanistic probe for rational immunotherapy design.Frontiers in immunology · 2026Review
- Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy.PloS one · 2026Article
- Immune reprogramming in the bone marrow microenvironment: a new perspective on the bone immune microenvironment of postmenopausal osteoporosis.Frontiers in immunology · 2026Review
- Bacillus Calmette-Guérin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer.Frontiers in immunology · 2026Article
- Review
- The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy.Cell death & disease · 2025Review
Corrections and comments
- Update of
Authors and funding
21 authors.
Andrew W DamanImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA.
Anthony C AntonelliImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Immunology Program, Sloan Kettering Institute, New York, NY, USA.
Gil Redelman-SidiInfectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lucinda PaddockDepartment of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shireen KhayatPharmacology Program, Weill Cornell Medicine Graduate School of Medical Sciences, New York, NY, USA.
Mythili KetavarapuDepartment of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA.
Jin Gyu CheongImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA.
Leonardo F JuradoDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada.
Anna BenjaminImmunology Program, Sloan Kettering Institute, New York, NY, USA.
Song JiangUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dughan AhimovicImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA.
Victoria R LawlessImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA.
Michael J BaleImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA.
Oleg LoutochinDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada.
Victor A McPhersonDepartment of Urology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Maziar DivangahiDepartment of Medicine, Department of Pathology, Department of Microbiology & Immunology, McGill University Health Centre, McGill International TB Centre, Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada.
Rachel E NiecImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Human Oncology and Pathogenesis Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dana Pe'erHoward Hughes Medical Institute, Chevy Chase, MD, USA; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eugene PietzakUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Steven Z JosefowiczImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA. Electronic address: szj2001@med.cornell.edu.
Michael S GlickmanImmunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Immunology Program, Sloan Kettering Institute, New York, NY, USA; Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: glickmam@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSENBERG, JONATHAN ERIC, SOLIT, DAVID B. · 2018 to 2024
$11.8MWeill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6MHistone Variant H3.3 as a Transcription Rheostat in the Immune SystemR01AI148416 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Steven Zvi Josefowicz · 2020 to 2026
$4.6MNext-Gen Oncopathology ProgramT32CA260293 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, BENJAMIN MONTEVERDE KLEAVELAND · 2022 to 2026
$1.4MImmunology and Microbial Pathogenesis Research Training ProgramT32AI134632 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI EHRT, SABINE, LI, MING · 2019 to 2023
$747kDescribing the Epigenetic Mechanisms in Control of Hematopoietic Development and Rapid Inflammatory ResponsesF31HL152706 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DAMAN, ANDREW · 2021 to 2023
$140kNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221745NCI NIH HHS T32 CA260293NHLBI NIH HHS F31 HL152706NIAID NIH HHS R01 AI148416NIAID NIH HHS T32 AI134632NIGMS NIH HHS T32 GM152349
Abstract
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown. We demonstrate that BCG administered in the bladder colonizes the bone marrow and, in both mice and humans, reprograms HSPCs to alter and amplify myelopoiesis. BCG-reprogrammed HSPCs are sufficient to confer augmented anti-tumor immunity through production of neutrophils, monocytes, and dendritic cells that broadly remodel the tumor microenvironment, drive T cell-dependent anti-tumor responses, and synergize with checkpoint blockade. We conclude that bladder BCG acts systemically through hematopoiesis, highlighting the broad potential of HSPC reprogramming to enhance the innate drivers of T cell-dependent tumor immunity.
Indexed as
BCG VaccineHematopoiesisImmunotherapyMyeloid CellsUrinary Bladder NeoplasmsAnimalsCellular ReprogrammingFemaleHematopoietic Stem CellsHumansMiceMice, Inbred C57BLMycobacterium bovisNeutrophilsTumor MicroenvironmentBCG VaccineBCGbladder cancerepigeneticshematopoiesisimmunotherapyinnate immune memorytrained immunitytumor immunity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.